Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Comparison of buprenorphine treatment for opioid dependence in 3 settings.

Miotto K, Hillhouse M, Donovick R, Cunningham-Rathner J, Charuvastra C, Torrington M, Esagoff AE, Ling W.

J Addict Med. 2012 Mar;6(1):68-76. doi: 10.1097/ADM.0b013e318233d621.

2.

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS.

N Engl J Med. 2006 Jul 27;355(4):365-74.

3.

Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.

Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA.

J Addict Med. 2012 Dec;6(4):274-9. doi: 10.1097/ADM.0b013e31826d1df3.

4.

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.

5.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

6.

Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.

Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M.

Drug Alcohol Depend. 2015 Nov 1;156:243-53. doi: 10.1016/j.drugalcdep.2015.09.020. Epub 2015 Sep 30.

7.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

8.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.

9.

Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W.

Contemp Clin Trials. 2013 Mar;34(2):196-204. doi: 10.1016/j.cct.2012.11.002. Epub 2012 Nov 16.

10.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
11.

Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.

Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS.

Addiction. 2016 May;111(5):874-82. doi: 10.1111/add.13259. Epub 2016 Jan 26.

PMID:
26639678
12.

Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

McDermott KA, Griffin ML, Connery HS, Hilario EY, Fiellin DA, Fitzmaurice GM, Weiss RD.

J Clin Psychiatry. 2015 Feb;76(2):189-94. doi: 10.4088/JCP.14m09096.

13.

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, McCarty D, Reid MS, Brown LS Jr, Maslansky R, Winhusen T, Babcock D, Brigham G, Muir J, Orr D, Buchan BJ, Horton T, Ling W.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):28-36. doi: 10.1016/j.drugalcdep.2008.06.016. Epub 2008 Sep 20.

14.

Drugs approved for opiate dependence.

[No authors listed]

FDA Consum. 2003 Jan-Feb;37(1):6. No abstract available.

15.
16.

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D; HPTN 058 study group..

Drug Alcohol Depend. 2014 Sep 1;142:139-45. doi: 10.1016/j.drugalcdep.2014.06.013. Epub 2014 Jun 19.

17.

Participant characteristics and buprenorphine dose.

Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):453-9. doi: 10.3109/00952990.2011.596974.

18.

Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?

Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM.

Drug Alcohol Depend. 2014 Jul 1;140:118-22. doi: 10.1016/j.drugalcdep.2014.04.005. Epub 2014 Apr 24.

19.

Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Rosenblatt RA, Andrilla CH, Catlin M, Larson EH.

Ann Fam Med. 2015 Jan-Feb;13(1):23-6. doi: 10.1370/afm.1735.

20.

Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.

Leshner AI.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S103-4. No abstract available.

PMID:
12738354

Supplemental Content

Support Center